the test device 1 according to fig1 & amp ; 2 comprises , as its main components , or preferably , a holder or distributor block 30 onto which a mouth mask 20 ( adapter ) and a mouthpiece 10 are or may be fitted . in the distributor block 30 , the mouthpiece 10 is connected to an inhalation channel 11 . the mouth mask 20 which surrounds the patient &# 39 ; s mouth p ( indicated purely diagrammatically by dashed lines in fig2 ) is fluidically connected to a channel 21 for stray air . the inhalation channel 11 and the stray air channel 21 preferably each have a flowmeter 12 , 22 , that are preferably constructed as thermal flow sensors . generally , the flowmeters may also be constructed in another form and / or differently . for example , a restrictor may be used for the flow measurement , the drop in pressure being detected by means of the restrictor . the mouthpiece 10 is connected to the inhalation channel 11 according to fig2 and preferably has a restrictor or shutter 13 at its entry end in the direction of flow , this restrictor or shutter 13 preferably being in the form of a perforated shutter that can be pushed or screwed on . in this way it is possible to simulate a flow resistance , such as occurs in inhalers . using different push - on perforated shutters with different flow aperture areas , rapid adaptation can be carried out . the main air flow through the inhalation channel 11 is determined using the flowmeter 12 . moreover , the pressure difference prevailing between the inhalation channel 11 and the stray air channel 21 surrounding it can be increased by means of a shutter 13 . stray air which is sucked in as a result of an imperfect seal between the mouthpiece 10 and the patient &# 39 ; s mouth p is detected by means of the mouth mask 20 and all flows together through the stray air channel 21 , so that all the stray air can be measured using the flowmeter 22 . the construction of the mouth mask 20 is such that it seals off the part of the patient &# 39 ; s face around the mouth . it is also possible for the mouth mask to have a bead - shaped region made of a flexible elastomeric material which fits closely against the facial area and thus produces an optimum seal between the face and the mouth mask 20 . in the distributor block 30 , the different air flows during inhalation are correspondingly apportioned to or detected in the inhalation channel 11 and stray air channel 21 . a coaxial connector 31 is preferably provided on the distributor block 30 and accommodates both the mouthpiece 10 and also the mouth mask 20 . the mouthpiece 10 and the mouth mask 20 that surrounds the mouthpiece 10 may be constructed so as to be pushed or screwed on . if necessary , the device 1 or the coaxial connector 31 may also have a preferably tubular connecting member 32 , as indicated in fig2 , to which the mouthpiece 10 that is to be tested is fixed or is capable of being fixed . alternatively , the connecting member 32 may also form part of the mouthpiece 10 or have been fixedly connected beforehand to the mouthpiece 10 that is to be tested , so that the connecting member 32 , together with the mouthpiece 10 , can then be inserted in the device 1 or adaptor 31 or distributor block 30 . however , other design solutions are also possible . as already explained , the amount of air that is inhaled is preferably detected upstream of the mouthpiece 10 , in this case , in the inhalation channel 11 . this quantity of air is also referred to as the inhaled air , for short . in addition , the amount of stray air that is sucked in during inhalation between the mouthpiece 10 and the patient &# 39 ; s mouth p or laterally past the mouthpiece 10 is preferably detected as stray air . preferably , the detection takes place in the stray air channel 21 . where the present invention refers to the measurement of flow or quantities of air , a volume flow or mass flow , i . e ., flow rate , or total quantities may be detected , as desired . the term “ flow measurement ” in particular should be interpreted correspondingly broadly . alternatively or additionally , the total quantities occurring over one or more inhalation processes can be detected or determined or evaluated from the flow rates . particularly preferably , the ratio of stray air to inhaled air or vice versa is determined or detected or evaluated . particularly preferably , the extent to which the abovementioned ratio or stray air varies as a function of the inhalation resistance , which can preferably be adjusted by means of a restrictor or by the shutter 13 , is detected or evaluated . the compounds listed below may be used in the device according to the invention on their own or in combination . in the compounds mentioned below , w is a pharmacologically active substance and is selected , for example , from among the betamimetics , anticholinergics , corticosteroids , pde4 - inhibitors , ltd4 - antagonists , egfr - inhibitors , dopamine agonists , hi - antihistamines , paf - antagonists and pi3 - kinase inhibitors . moreover , double or triple combinations of w may be combined and used in the device according to the invention . combinations of w might be , for example : w denotes a betamimetic , combined with an anticholinergic , corticosteroid , pde4 - inhibitor , egfr - inhibitor or ltd4 - antagonist , w denotes an anticholinergic , combined with a betamimetic , corticosteroid , pde4 - inhibitor , egfr - inhibitor or ltd4 - antagonist , the compounds used as betamimetics are preferably compounds selected from among albuterol , arformoterol , bambuterol , bitolterol , broxaterol , carbuterol , clenbuterol , fenoterol , formoterol , hexoprenaline , ibuterol , isoetharine , isoprenaline , levosalbutamol , mabuterol , meluadrine , metaproterenol , orciprenaline , pirbuterol , procaterol , reproterol , rimiterol , ritodrine , salmefamol , salmeterol , soterenol , sulphonterol , terbutaline , tiaramide , tolubuterol , zinterol , chf - 1035 , hoku - 81 , kul - 1248 and 3 -( 4 -{ 6 -[ 2 - hydroxy - 2 -( 4 - hydroxy - 3 - hydroxymethyl - phenyl )- ethylamino ]- hexyloxy }- butyl )- benzyl - sulphonamide 5 -[ 2 -( 5 , 6 - diethyl - indan - 2 - ylamino )- 1 - hydroxy - ethyl ]- 8 - hydroxy - 1h - quinolin - 2 - one 4 - hydroxy - 7 -[ 2 -{[ 2 -{[ 3 -( 2 - phenylethoxy ) propyl ] sulphonyl } ethyl ]- amino } ethyl ]- 2 ( 3h )- benzothiazolone 1 -( 2 - fluoro - 4 - hydroxyphenyl )- 2 -[ 4 -( 1 - benzimidazolyl )- 2 - methyl - 2 - butylamino ] ethanol 1 -[ 3 -( 4 - methoxybenzyl - amino )- 4 - hydroxyphenyl ]- 2 -[ 4 -( 1 - benzimidazolyl )- 2 - methyl - 2 - butylamino ] ethanol 1 -[ 2h - 5 - hydroxy - 3 - oxo - 4h - 1 , 4 - benzoxazin - 8 - yl ]- 2 -[ 3 -( 4 - n , n - dimethylaminophenyl )- 2 - methyl - 2 - propylamino ] ethanol 1 -[ 2h - 5 - hydroxy - 3 - oxo - 4h - 1 , 4 - benzoxazin - 8 - yl ]- 2 -[ 3 -( 4 - methoxyphenyl )- 2 - methyl - 2 - propylamino ] ethanol 1 -[ 2h - 5 - hydroxy - 3 - oxo - 4h - 1 , 4 - benzoxazin - 8 - yl ]- 2 -[ 3 -( 4 - n - butyloxyphenyl )- 2 - methyl - 2 - propylamino ] ethanol 1 -[ 2h - 5 - hydroxy - 3 - oxo - 4h - 1 , 4 - benzoxazin - 8 - yl ]- 2 -{ 4 -[ 3 -( 4 - methoxyphenyl )- 1 , 2 , 4 - triazol - 3 - yl ]- 2 - methyl - 2 - butylamino } ethanol 5 - hydroxy - 8 -( 1 - hydroxy - 2 - isopropylaminobutyl )- 2h - 1 , 4 - benzoxazin - 3 -( 4h )- one 1 -( 4 - amino - 3 - chloro - 5 - trifluoromethylphenyl )- 2 - tert .- butylamino ) ethanol 6 - hydroxy - 8 -{ 1 - hydroxy - 2 -[ 2 -( 4 - methoxy - phenyl )- 1 , 1 - dimethyl - ethylamino ]- ethyl }- 4h - benzo [ 1 , 4 ] oxazin - 3 - one 6 - hydroxy - 8 -{ 1 - hydroxy - 2 -[ 2 -( ethyl 4 - phenoxy - acetate )- 1 , 1 - dimethyl - ethylamino ]- ethyl }- 4h - benzo [ 1 , 4 ] oxazin - 3 - one 6 - hydroxy - 8 -{ 1 - hydroxy - 2 -[ 2 -( 4 - phenoxy - acetic acid )- 1 , 1 - dimethyl - ethylamino ]- ethyl }- 4h - benzo [ 1 , 4 ] oxazin - 3 - one 8 -{ 2 -[ 1 , 1 - dimethyl - 2 -( 2 , 4 , 6 - trimethylphenyl )- ethylamino ]- 1 - hydroxy - ethyl }- 6 - hydroxy - 4h - benzo [ 1 , 4 ] oxazin - 3 - one 6 - hydroxy - 8 -{ 1 - hydroxy - 2 -[ 2 -( 4 - hydroxy - phenyl )- 1 , 1 - dimethyl - ethylamino ]- ethyl }- 4h - benzo [ 1 , 4 ] oxazin - 3 - one 6 - hydroxy - 8 -{ 1 - hydroxy - 2 -[ 2 -( 4 - isopropyl - phenyl )- 1 . 1 dimethyl - ethylamino ]- ethyl }- 4h - benzo [ 1 , 4 ] oxazin - 3 - one 8 -{ 2 -[ 2 -( 4 - ethyl - phenyl )- 1 , 1 - dimethyl - ethylamino ]- 1 - hydroxy - ethyl }- 6 - hydroxy - 4h - benzo [ 1 , 4 ] oxazin - 3 - one 8 -{ 2 -[ 2 -( 4 - ethoxy - phenyl )- 1 , 1 - dimethyl - ethylamino ]- 1 - hydroxy - ethyl }- 6 - hydroxy - 4h - benzo [ 1 , 4 ] oxazin - 3 - one 4 -( 4 -{ 2 -[ 2 - hydroxy - 2 -( 6 - hydroxy - 3 - oxo - 3 , 4 - dihydro - 2h - benzo [ 1 , 4 ] oxazin - 8 - yl )- ethylamino ]- 2 - methyl - propyl }- phenoxy )- butyric acid 8 -{ 2 -[ 2 -( 3 . 4 difluoro - phenyl )- 1 , 1 - dimethyl - ethylamino ]- 1 - hydroxy - ethyl }- 6 - hydroxy - 4h - benzo [ 1 , 4 ] oxazin - 3 - one 1 -( 4 - ethoxy - carbonylamino - 3 - cyano - 5 - fluorophenyl )- 2 -( tert - butylamino ) ethanol 2 - hydroxy - 5 -( 1 - hydroxy - 2 -{ 2 -[ 4 -( 2 - hydroxy - 2 - phenyl - ethylamino )- phenyl ]- ethylamino }- ethyl )- benzaldehyde n -[ 2 - hydroxy - 5 -( 1 - hydroxy - 2 -{ 2 -[ 4 -( 2 - hydroxy - 2 - phenyl - ethylamino )- phenyl ]- ethylamino }- ethyl )- phenyl ]- formamide 8 - hydroxy - 5 -( 1 - hydroxy - 2 -{ 2 -[ 4 -( 6 - methoxy - biphenyl - 3 - ylamino )- phenyl ]- ethylamino }- ethyl )- 1h - quinolin - 2 - one 8 - hydroxy - 5 -[ 1 - hydroxy - 2 -( 6 - phenethylamino - hexylamino )- ethyl ]- 1h - quinolin - 2 - one 5 -[ 2 -( 2 -{ 4 -[ 4 -( 2 - amino - 2 - methyl - propoxy )- phenylamino ]- phenyl }- ethylamino )- 1 - hydroxy - ethyl ]- 8 - hydroxy - 1h - quinolin - 2 - one [ 3 -( 4 -{ 6 -[ 2 - hydroxy - 2 -( 4 - hydroxy - 3 - hydroxymethyl - phenyl )- ethylamino ]- hexyloxy }- butyl )- 5 - methyl - phenyl ]- urea 4 -( 2 -{ 6 -[ 2 -( 2 , 6 - dichloro - benzyloxy )- ethoxy ]- hexylamino }- 1 - hydroxy - ethyl )- 2 - hydroxymethyl - phenol 3 -( 4 -{ 6 -[ 2 - hydroxy - 2 -( 4 - hydroxy - 3 - hydroxymethyl - phenyl )- ethylamino ]- hexyloxy }- butyl )- benzylsulphonamide 3 -( 3 -{ 7 -[ 2 - hydroxy - 2 -( 4 - hydroxy - 3 - hydroxymethyl - phenyl )- ethylamino ]- heptyloxy }- propyl )- benzylsulphonamide 4 -( 2 -{ 6 -[ 4 -( 3 - cyclopentanesulphonyl - phenyl )- butoxy ]- hexylamino }- 1 - hydroxy - ethyl )- 2 - hydroxymethyl - phenol n - adamantan - 2 - yl - 2 -( 3 -{ 2 -[ 2 - hydroxy - 2 -( 4 - hydroxy - 3 - hydroxymethyl - phenyl )- ethylamino ]- propyl }- phenyl )- acetamide optionally in the form of the racemates , enantiomers , diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts , solvates or hydrates thereof . according to the invention the acid addition salts of the betamimetics are preferably selected from among the hydrochloride , hydrobromide , hydriodide , hydrosulphate , hydrophosphate , hydromethanesulphonate , hydronitrate , hydromaleate , hydroacetate , hydrocitrate , hydrofumarate , hydrotartrate , hydroxalate , hydrosuccinate , hydrobenzoate and hydro - p - toluenesulphonate . the anticholinergics used are preferably compounds selected from among the tiotropium salts , preferably the bromide salt , oxitropium salts , preferably the bromide salt , flutropium salts , preferably the bromide salt , ipratropium salts , preferably the bromide salt , glycopyrronium salts , preferably the bromide salt , trospium salts , preferably the chloride salt , tolterodine . in the above - mentioned salts the cations are the pharmacologically active constituents . as anions the above - mentioned salts may preferably contain the chloride , bromide , iodide , sulphate , phosphate , methanesulphonate , nitrate , maleate , acetate , citrate , fumarate , tartrate , oxalate , succinate , benzoate or p - toluenesulphonate , while chloride , bromide , iodide , sulphate , methanesulphonate or p - toluenesulphonate are preferred as counter - ions . of all the salts the chlorides , bromides , iodides and methanesulphonates are particularly preferred . other preferred anticholinergics are selected from among the salts of formula ac - 1 wherein x − denotes an anion with a single negative charge , preferably an anion selected from among the fluoride , chloride , bromide , iodide , sulphate , phosphate , methanesulphonate , nitrate , maleate , acetate , citrate , fumarate , tartrate , oxalate , succinate , benzoate and p - toluenesulphonate , preferably an anion with a single negative charge , particularly preferably an anion selected from among the fluoride , chloride , bromide , methanesulphonate and p - toluenesulphonate , particularly preferably bromide , optionally in the form of the racemates , enantiomers or hydrates thereof . of particular importance are those pharmaceutical combinations which contain the enantiomers of formula ac - 1 - en wherein x − may have the above - mentioned meanings . other preferred anticholinergics are selected from the salts of formula ac - 2 wherein r denotes either methyl or ethyl and wherein x − may have the above - mentioned meanings . in an alternative embodiment the compound of formula ac - 2 may also be present in the form of the free base ac - 2 - base . tropenol 2 , 2 - diphenylpropionate methobromide , scopine 2 , 2 - diphenylpropionate methobromide , scopine 2 - fluoro - 2 , 2 - diphenyl acetate methobromide , tropenol 2 - fluoro - 2 , 2 - diphenylacetate methobromide ; tropenol 3 , 3 ′, 4 , 4 ′- tetrafluorobenzilate methobromide , scopine 3 , 3 ′, 4 , 4 ′- tetrafluorobenzilate methobromide , tropenol 4 , 4 ′- difluorobenzilate methobromide , scopine 4 , 4 ′- difluorobenzilate methobromide , tropenol 3 , 3 ′- difluorobenzilate methobromide , scopine 3 , 3 ′- difluorobenzilate methobromide ; tropenol 9 - hydroxy - fluorene - 9 - carboxylate methobromide ; tropenol 9 - fluoro - fluorene - 9 - carboxylate methobromide ; scopine 9 - hydroxy - fluorene - 9 - carboxylate methobromide ; scopine 9 - fluoro - fluorene - 9 - carboxylate methobromide ; tropenol 9 - methyl - fluorene - 9 - carboxylate methobromide ; scopine 9 - methyl - fluorene - 9 - carboxylate methobromide ; cyclopropyltropine benzilate methobromide ; cyclopropyltropine 2 , 2 - diphenylpropionate methobromide ; cyclopropyltropine 9 - hydroxy - xanthene - 9 - carboxylate methobromide ; cyclopropyltropine 9 - methyl - fluorene - 9 - carboxylate methobromide ; cyclopropyltropine 9 - methyl - xanthene - 9 - carboxylate methobromide ; cyclopropyltropine 9 - hydroxy - fluorene - 9 - carboxylate methobromide ; cyclopropyltropine methyl 4 , 4 ′- difluorobenzilate methobromide . tropenol 9 - hydroxy - xanthene - 9 - carboxylate methobromide ; scopine 9 - hydroxy - xanthene - 9 - carboxylate methobromide ; tropenol 9 - methyl - xanthene - 9 - carboxylate methobromide ; scopine 9 - methyl - xanthene - 9 - carboxylate methobromide ; tropenol 9 - ethyl - xanthene - 9 - carboxylate methobromide ; tropenol 9 - difluoromethyl - xanthene - 9 - carboxylate methobromide ; scopine 9 - hydroxymethyl - xanthene - 9 - carboxylate methobromide , the above - mentioned compounds may also be used as salts within the scope of the present invention , wherein instead of the methobromide the salts metho - x are used , wherein x may have the meanings given hereinbefore for x − . as corticosteroids it is preferable to use compounds selected from among beclomethasone , betamethasone , budesonide , butixocort , ciclesonide , deflazacort , dexamethasone , etiprednol , flunisolide , fluticasone , loteprednol , mometasone , prednisolone , prednisone , rofleponide , triamcinolone , rpr - 106541 , ns - 126 , st - 26 and optionally in the form of the racemates , enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof , the solvates and / or hydrates thereof . any reference to steroids includes a reference to any salts or derivatives , hydrates or solvates thereof which may exist . examples of possible salts and derivatives of the steroids may be : alkali metal salts , such as for example sodium or potassium salts , sulphobenzoates , phosphates , isonicotinates , acetates , dichloroacetates , propionates , dihydrogen phosphates , palmitates , pivalates or furoates . pde4 - inhibitors which may be used are preferably compounds selected from among enprofyllin , theophyllin , roflumilast , ariflo ( cilomilast ), tofimilast , pumafentrin , lirimilast , arofyllin , atizoram , d - 4418 , bay - 198004 , by343 , cp - 325 . 366 , d - 4396 ( sch - 351591 ), awd - 12 - 281 ( gw - 842470 ), ncs - 613 , cdp - 840 , d - 4418 , pd - 168787 , t - 440 , t - 2585 , v - 11294a , ci - 1018 , cdc - 801 , cdc - 3052 , d - 22888 , ym - 58997 , z - 15370 and n -( 3 , 5 - dichloro - 1 - oxo - pyridin - 4 - yl )- 4 - difluoromethoxy - 3 - cyclopropylmethoxybenzamide (−) p -[( 4ar *, 10bs *)- 9 - ethoxy - 1 , 2 , 3 , 4 , 4a , 10b - hexahydro - 8 - methoxy - 2 - methylbenzo [ s ][ 1 , 6 ] naphthyridin - 6 - yl ]- n , n - diisopropylbenzamide ( r )-(+)- 1 -( 4 - bromobenzyl )- 4 -[( 3 - cyclopentyloxy )- 4 - methoxyphenyl ]- 2 - pyrrolidone 3 -( cyclopentyloxy - 4 - methoxyphenyl )- 1 -( 4 - n ′-[ n - 2 - cyano - 5 - methyl - isothioureido ] benzyl )- 2 - pyrrolidone cis [ 4 - cyano - 4 -( 3 - cyclopentyloxy - 4 - methoxyphenyl ) cyclohexane - 1 - carboxylic acid ] 2 - carbomethoxy - 4 - cyano - 4 -( 3 - cyclopropylmethoxy - 4 - difluoromethoxy - phenyl ) cyclohexan - 1 - one cis [ 4 - cyano - 4 -( 3 - cyclopropylmethoxy - 4 - difluoromethoxyphenyl ) cyclohexan - 1 - ol ] ( r )-(+)- ethyl [ 4 -( 3 - cyclopentyloxy - 4 - methoxyphenyl ) pyrrolidin - 2 - ylidene ] acetate ( s )-(−)- ethyl [ 4 -( 3 - cyclopentyloxy - 4 - methoxyphenyl ) pyrrolidin - 2 - ylidene ] acetate 9 - cyclopentyl - 5 , 6 - dihydro - 7 - ethyl - 3 -( 2 - thienyl )- 9h - pyrazolo [ 3 , 4 - c ]- 1 , 2 , 4 - triazolo [ 4 , 3 - a ] pyridine 9 - cyclopentyl - 5 , 6 - dihydro - 7 - ethyl - 3 -( tert - butyl )- 9h - pyrazolo [ 3 , 4 - c ]- 1 , 2 , 4 - triazolo [ 4 , 3 - a ] pyridine optionally in the form of the racemates , enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts thereof , the solvates and / or hydrates thereof . according to the invention the acid addition salts of the pde4 inhibitors are preferably selected from among the hydrochloride , hydrobromide , hydriodide , hydrosulphate , hydrophosphate , hydromethanesulphonate , hydronitrate , hydromaleate , hydroacetate , hydrocitrate , hydrofumarate , hydrotartrate , hydroxalate , hydrosuccinate , hydrobenzoate and hydro - p - toluenesulphonate . the ltd4 - antagonists used are preferably compounds selected from among montelukast , pranlukast , zafirlukast , mcc - 847 ( zd - 3523 ), mn - 001 , men - 91507 ( lm - 1507 ), vuf - 5078 , vuf - k - 8707 , l - 733321 and optionally in the form of the racemates , enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts , solvates and / or hydrates thereof . according to the invention these acid addition salts are preferably selected from among the hydrochloride , hydrobromide , hydriodide , hydrosulphate , hydrophosphate , hydromethanesulphonate , hydronitrate , hydromaleate , hydroacetate , hydrocitrate , hydrofumarate , hydrotartrate , hydroxalate , hydrosuccinate , hydrobenzoate and hydro - p - toluenesulphonate . by salts or derivatives which the ltd4 - antagonists may optionally be capable of forming are meant , for example : alkali metal salts , such as for example sodium or potassium salts , alkaline earth metal salts , sulphobenzoates , phosphates , isonicotinates , acetates , propionates , dihydrogen phosphates , palmitates , pivalates or furoates . egfr - inhibitors which may be used are preferably compounds selected from among cetuximab , trastuzumab , abx - egf , mab icr - 62 and 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino })- 7 - cyclopropylmethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - diethylamino )- 1 - oxo - 2 - buten - 1 - yl ]- amino }- 7 - cyclopropylmethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopropylmethoxy - quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -{[ 4 -( morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopentyloxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{[ 4 -(( r )- 6 - methyl - 2 - oxo - morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopropylmethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{[ 4 -(( r )- 6 - methyl - 2 - oxo - morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 -[( s )-( tetrahydrofuran - 3 - yl ) oxy ]- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{[ 4 -(( r )- 2 - methoxymethyl - 6 - oxo - morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopropylmethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 2 -(( s )- 6 - methyl - 2 - oxo - morpholin - 4 - yl )- ethoxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -({ 4 -[ n -( 2 - methoxy - ethyl )- n - methyl - amino ]- 1 - oxo - 2 - buten - 1 - yl } amino )- 7 - cyclopropylmethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopentyloxy - quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -{[ 4 -( n , n - to -( 2 - methoxy - ethyl )- amino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopropylmethoxy - quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -({ 4 -[ n -( 2 - methoxy - ethyl )- n - ethyl - amino ]- 1 - oxo - 2 - buten - 1 - yl } amino )- 7 - cyclopropylmethoxy - quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -({ 4 -[ n -( 2 - methoxy - ethyl )- n - methyl - amino ]- 1 - oxo - 2 - buten - 1 - yl } amino )- 7 - cyclopropylmethoxy - quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -({ 4 -[ n -( tetrahydropyran - 4 - yl )- n - methyl - amino ]- 1 - oxo - 2 - buten - 1 - yl } amino )- 7 - cyclopropylmethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 -(( r )- tetrahydrofuran - 3 - yloxy )- quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 -(( s )- tetrahydrofuran - 3 - yloxy )- quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -({ 4 -[ n -( 2 - methoxy - ethyl )- n - methyl - amino ]- 1 - oxo - 2 - buten - 1 - yl } amino )- 7 - cyclopentyloxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n - cyclopropyl - n - methyl - amino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - cyclopentyloxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 -[( r )-( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 -[( s )-( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 . 7 to -( 2 - methoxy - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 7 -[ 3 -( morpholin - 4 - yl )- propyloxy ]- 6 -[( vinyl - carbonyl ) amino ]- quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -( 4 - hydroxy - phenyl )- 7h - pyrrolo [ 2 , 3 - d ] pyrimidine 3 - cyano - 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( n , n - dimethylamino )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - ethoxy - quinoline 4 -{[ 3 - chloro - 4 -( 3 - fluoro - benzyloxy )- phenyl ] amino }- 6 -( 5 -{[( 2 - methanesulphonyl - ethyl ) amino ] methyl }- furan - 2 - yl ) quinazoline 4 -[( r )-( 1 - phenyl - ethyl ) amino ]- 6 -{[ 4 -(( r )- 6 - methyl - 2 - oxo - morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -{[ 4 -( morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- 7 -[( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - chloro - 4 - fluorophenyl ) amino ]- 6 -({ 4 -[ n , n - to -( 2 - methoxy - ethyl )- amino ]- 1 - oxo - 2 - buten - 1 - yl } amino )- 7 -[( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -{[ 4 -( 5 . 5 dimethyl - 2 - oxo - morpholin - 4 - yl )- 1 - oxo - 2 - buten - 1 - yl ] amino }- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 2 -( 2 , 2 - dimethyl - 6 - oxo - morpholin - 4 - yl )- ethoxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 2 -( 2 , 2 - dimethyl - 6 - oxo - morpholin - 4 - yl )- ethoxy ]- 7 -[( r )-( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 7 -[ 2 -( 2 , 2 - dimethyl - 6 - oxo - morpholin - 4 - yl )- ethoxy ]- 6 -[( s )-( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 2 -[ 4 -( 2 - oxo - morpholin - 4 - yl )- piperidin - 1 - yl ]- ethoxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 1 -( tert .- butyloxycarbonyl )- piperidin - 4 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( trans - 4 - amino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( trans - 4 - methanesulphonylamino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( tetrahydropyran - 3 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - methyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( morpholin - 4 - yl ) carbonyl ]- piperidin - 4 - yl - oxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( methoxymethyl ) carbonyl ]- piperidin - 4 - yl - oxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( piperidin - 3 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 1 -( 2 - acetylamino - ethyl )- piperidin - 4 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( tetrahydropyran - 4 - yloxy )- 7 - ethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -(( s )- tetrahydrofuran - 3 - yloxy )- 7 - hydroxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( tetrahydropyran - 4 - yloxy )- 7 -( 2 - methoxy - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ trans - 4 -[( dimethylamino ) sulphonylamino ]- cyclohexan - 1 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ trans - 4 -[( morpholin - 4 - yl ) carbonylamino ]- cyclohexan - 1 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ trans - 4 -[( morpholin - 4 - yl ) sulphonylamino ]- cyclohexan - 1 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( tetrahydropyran - 4 - yloxy )- 7 -( 2 - acetylamino - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( tetrahydropyran - 4 - yloxy )- 7 -( 2 - methanesulphonylamino - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( piperidin - 1 - yl ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - aminocarbonylmethyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 -{ n -[( tetrahydropyran - 4 - yl ) carbonyl ]- n - methyl - amino }- cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 -{ n -[( morpholin - 4 - yl ) carbonyl ]- n - methyl - amino }- cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 -{ n -[( morpholin - 4 - yl ) sulphonyl ]- n - methyl - amino )}- cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( trans - 4 - ethanesulphonylamino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - methanesulphonyl - piperidin - 4 - yloxy )- 7 - ethoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - methanesulphonyl - piperidin - 4 - yloxy )- 7 -( 2 - methoxy - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 1 -( 2 - methoxy - acetyl )- piperidin - 4 - yloxy ]- 7 -( 2 - methoxy - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 - acetylamino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -[ 1 -( tert .- butyloxycarbonyl )- piperidin - 4 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -( tetrahydropyran - 4 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 -{ n -[( piperidin - 1 - yl ) carbonyl ]- n - methyl - amino )}- cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 -{ n -[( 4 - methyl - piperazin - 1 - yl ) carbonyl ]- n - methyl - amino )}- cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ cis - 4 -[( morpholin - 4 - yl ) carbonylamino ]- cyclohexan - 1 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[ 2 -( 2 - oxopyrrolidin - 1 - yl ) ethyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( morpholin - 4 - yl ) carbonyl ]- piperidin - 4 - yloxy }- 7 -( 2 - methoxy - ethoxy )- quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -( 1 - acetyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -( 1 - methyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -( 1 - methanesulphonyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - methyl - piperidin - 4 - yloxy )- 7 ( 2 - methoxy - ethoxy )- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - isopropyloxycarbonyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( cis - 4 - methylamino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ cis - 4 -[ n -( 2 - methoxy - acetyl )- n - methyl - amino ]- cyclohexan - 1 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -( piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -[ 1 -( 2 - methoxy - acetyl )- piperidin - 4 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - ethynyl - phenyl ) amino ]- 6 -{ 1 -[( morpholin - 4 - yl ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( cis - 2 , 6 - dimethyl - morpholin - 4 - yl ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( 2 - methyl - morpholin - 4 - yl ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( s , s )-( 2 - oxa - 5 - aza - bicyclo [ 2 , 2 , 1 ] hept - 5 - yl ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( n - methyl - n - 2 - methoxyethyl - amino ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - ethyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( 2 - methoxyethyl ) carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -{ 1 -[( 3 - methoxypropyl - amino )- carbonyl ]- piperidin - 4 - yloxy }- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ cis - 4 -( n - methanesulphonyl - n - methyl - amino )- cyclohexan - 1 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ cis - 4 -( n - acetyl - n - methyl - amino )- cyclohexan - 1 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( trans - 4 - methylamino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ trans - 4 -( n - methanesulphonyl - n - methyl - amino )- cyclohexan - 1 - yloxy ]- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( trans - 4 - dimethylamino - cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( trans - 4 -{ n -[( morpholin - 4 - yl ) carbonyl ]- n - methyl - amino }- cyclohexan - 1 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -[ 2 -( 2 , 2 - dimethyl - 6 - oxo - morpholin - 4 - yl )- ethoxy ]- 7 -[( s )-( tetrahydrofuran - 2 - yl ) methoxy ]- quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - methanesulphonyl - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline 4 -[( 3 - chloro - 4 - fluoro - phenyl ) amino ]- 6 -( 1 - cyano - piperidin - 4 - yloxy )- 7 - methoxy - quinazoline optionally in the form of the racemates , enantiomers , diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts , solvates or hydrates thereof . according to the invention these acid addition salts are preferably selected from among the hydrochloride , hydrobromide , hydriodide , hydrosulphate , hydrophosphate , hydromethanesulphonate , hydronitrate , hydromaleate , hydroacetate , hydrocitrate , hydrofumarate , hydrotartrate , hydroxalate , hydrosuccinate , hydrobenzoate and hydro - p - toluenesulphonate . the dopamine agonists used are preferably compounds selected from among bromocriptin , cabergoline , alpha - dihydroergocryptine , lisuride , pergolide , pramipexol , roxindol , ropinirol , talipexol , tergurid and viozan , optionally in the form of the racemates , enantiomers , diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts , solvates or hydrates thereof . according to the invention these acid addition salts are preferably selected from among the hydrochloride , hydrobromide , hydriodide , hydrosulphate , hydrophosphate , hydromethanesulphonate , hydronitrate , hydromaleate , hydroacetate , hydrocitrate , hydrofumarate , hydrotartrate , hydrooxalate , hydrosuccinate , hydrobenzoate and hydro - p - toluenesulphonate . h1 - antihistamines which may be used are preferably compounds selected from among epinastine , cetirizine , azelastine , fexofenadine , levocabastine , loratadine , mizolastine , ketotifen , emedastine , dimetindene , clemastine , bamipine , cexchlorpheniramine , pheniramine , doxylamine , chlorophenoxamine , dimenhydrinate , diphenhydramine , promethazine , ebastine , desloratidine and meclozine , optionally in the form of the racemates , enantiomers , diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts , solvates or hydrates thereof . according to the invention these acid addition salts are preferably selected from among the hydrochloride , hydrobromide , hydriodide , hydrosulphate , hydrophosphate , hydromethanesulphonate , hydronitrate , hydromaleate , hydroacetate , hydrocitrate , hydrofumarate , hydrotartrate , hydroxalate , hydrosuccinate , hydrobenzoate and hydro - p - toluenesulphonate . as pharmaceutically active substances , substance formulations or substance mixtures , any inhalable compounds may be used , also including inhalable macromolecules as disclosed in ep 1 003 478 . preferably , substances , substance formulations or substance mixtures are used to treat respiratory complaints , which are used by inhalation . in addition , the compound may come from the group of ergot alkaloid derivatives , the triptans , the cgrp - inhibitors , the phosphodiesterase - v inhibitors , optionally in the form of the racemates , enantiomers or diastereomers thereof , optionally in the form of the pharmacologically acceptable acid addition salts , the solvates and / or hydrates thereof .
a device for testing the seal between the lips of a user and a mouthpiece during inhalation . the mouthpiece is connected to an inhalation channel provided with a first flowmeter , and the device has an stray air channel which extends around the lips and which is provided with a second flowmeter .